Drugs / GB5121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05242146 | May 2022 → May 2023 | central nervous system non-hodgkin lymphoma | Gossamer Bio USA, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB5121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05242146 ↗ |
| Route | Oral | “GB5121 orally twice per day (BID)” NCT05242146 ↗ |